CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
cisplatin +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00248495
NCT00248495Phase 2Completed
CompareCT.gov

Molecular and Genetic Changes in Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Cisplatin and Alimta - Phase II Study

Roswell Park Cancer Institute·interventional·Posted Nov 4, 2005·Updated Jul 12, 2017

In Brief

A Phase 2 clinical trial evaluating cisplatin, pemetrexed disodium, and 3 other interventions for Lung Cancer. Completed, enrolled 38 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them before and after surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving pemetrexed disodium and cisplatin before and after surgery works in treating patients with stage I, stage II, or stage III non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 2005
Enrollment StartJun 8, 2005
Primary CompletionApr 29, 2011
Study CompletionApr 5, 2017
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 20.7 years ago

Interventions

cisplatindrug

Given IV

pemetrexed disodiumdrug

Given IV

adjuvant therapyprocedure

Metastasis prevention/control

conventional surgeryprocedure

Undergoing tissue removal

neoadjuvant therapyprocedure

Tumor Reduction